Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
siCSF2#1 is a small interfering RNA (siRNA) designed to silence the expression of Colony-Stimulating Factor 2 (CSF2), also known as Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF). In colorectal cancer (CRC), CSF2 has been identified as a promoter of chemoresistance to agents like 5-fluorouracil (5FU) and oxaliplatin (OXP) by activating the Notch signaling pathway. By targeting CSF2 mRNA for degradation, siCSF2#1 reduces the levels of CSF2 protein, which in turn inhibits Notch signaling and sensitizes CRC cells to chemotherapy. This molecule is primarily used as a research tool in preclinical studies to investigate the molecular mechanisms of drug resistance and to validate CSF2 as a potential therapeutic target in oncology.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on siCSF2#1.